Peptide agonists of GLP-1 activity
First Claim
Patent Images
1. A peptide consisting of any one of the following sequences:
- a) H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-(Lys)6-NH2 (des-Pro36-exendin-4(1-39)-Lys6-NH2) (SEQ ID NO;
93), b) H-Lys6-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-(Lys)6-NH2 (H-Lys6-des Pro36exendin-4(1-39)-Lys6-NH2) (SEQ ID NO;
149), c) H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-NH2 (H-des Pro36,Pro37,Pro38exendin-4(1-39)-NH2) (SEQ ID NO;
132), d) H-Lys-Lys-Lys-Lys-Lys-Lys-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-NH2 (H-(Lys)6-des Pro36,Pro37,Pro38exendin-4(1-39)-NH2), (SEQ ID NO;
134), e) H-Asn-Glu-Glu-Glu-Glu-Glu-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-NH2 (H-Asn-(Glu)5-des Pro36,Pro37, Pro38exendin-4(1-39)-NH2) (SEQ ID NO;
137), f) H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-(Lys)6-NH2 (des Pro36, Pro37,Pro38exendin-4(1-39)-(Lys)6-NH2) (SEQ ID NO;
133), g) H-(Lys)6-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-(Lys)6-NH2 (H-(Lys)6-des Pro36,Pro37,Pro38exendin-4(1-39)-(Lys)6-NH2) (SEQ ID NO;
135), h) H-Asp-Glu-Glu-Glu-Glu-Glu-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-(Lys)6-NH2 (H-Asn-(Glu)5-des Pro36,Pro37,Pro38exendin-4(1-39)-(Lys)6-NH2) (SEQ ID NO;
136);
or a pharmaceutically acceptable salt thereof.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.
-
Citations
2 Claims
-
1. A peptide consisting of any one of the following sequences:
-
a) H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-(Lys)6-NH2 (des-Pro36-exendin-4(1-39)-Lys6-NH2) (SEQ ID NO;
93),b) H-Lys6-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-(Lys)6-NH2 (H-Lys6-des Pro36exendin-4(1-39)-Lys6-NH2) (SEQ ID NO;
149),c) H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-NH2 (H-des Pro36,Pro37,Pro38exendin-4(1-39)-NH2) (SEQ ID NO;
132),d) H-Lys-Lys-Lys-Lys-Lys-Lys-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-NH2 (H-(Lys)6-des Pro36,Pro37,Pro38exendin-4(1-39)-NH2), (SEQ ID NO;
134),e) H-Asn-Glu-Glu-Glu-Glu-Glu-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-NH2 (H-Asn-(Glu)5-des Pro36,Pro37, Pro38exendin-4(1-39)-NH2) (SEQ ID NO;
137),f) H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-(Lys)6-NH2 (des Pro36, Pro37,Pro38exendin-4(1-39)-(Lys)6-NH2) (SEQ ID NO;
133),g) H-(Lys)6-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-(Lys)6-NH2 (H-(Lys)6-des Pro36,Pro37,Pro38exendin-4(1-39)-(Lys)6-NH2) (SEQ ID NO;
135),h) H-Asp-Glu-Glu-Glu-Glu-Glu-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-(Lys)6-NH2 (H-Asn-(Glu)5-des Pro36,Pro37,Pro38exendin-4(1-39)-(Lys)6-NH2) (SEQ ID NO;
136);
or a pharmaceutically acceptable salt thereof. - View Dependent Claims (2)
-
Specification